BioCentury
ARTICLE | Company News

Swiss Pharma files IPR challenge to Biogen's Tysabri

April 20, 2016 1:00 AM UTC

Swiss Pharma International AG (Zurich, Switzerland) filed three inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Biogen Inc. (NASDAQ:BIIB) covering multiple sclerosis drug Tysabri natalizumab.

Swiss Pharma is alleging that claims in Biogen's U.S. Patents Nos. 8,815,236, 8,900,577 and 8,349,321 are unpatentable on the grounds of obviousness based on prior art. The '236 patent relates to a method of use of a stable aqueous formulation of natalizumab with a phosphate buffer, a polysorbate and sodium chloride to treat MS or Crohn's disease. The '577 and '321 patents cover immunoglobulin formulations and methods of preparation. ...